Director, Global Product Strategy - Lung Cancer Therapies
Scorpion Therapeutics, Berkeley Heights, New Jersey, us, 07922
Role Summary
Director, Lung Cancer Portfolio, reporting to the VP of Lung Cancer Therapies, based in New Jersey, US. This strategic, science-driven leader shapes the future of a high-priority oncology indication, focusing on new product planning and early commercial strategy. The role requires hands-on leadership, deep oncology market insight, and the ability to position early assets for future success in a global environment, with presence in the US and Germany. Responsibilities
Lead global commercial strategy development for the lung cancer portfolio, with a focus on indication prioritization, early positioning, and value-focused lifecycle strategy Drive new product planning activities from preclinical/early clinical through registrational development, supporting strategic TPP shaping, unmet need assessment, competitive differentiation, and commercial viability Partner cross-functionally with R&D, clinical development, translational research, regulatory, and medical affairs to embed commercial perspectives into key decisions Lead or co-lead commercial input into early launch readiness planning, with emphasis on evidence strategy, access considerations, and strategic stakeholder engagement Contribute to cross-functional governance processes, development strategy forums, and scenario planning efforts Support external interactions where needed (e.g., advisory boards, co-development partners, select KOL discussions) in alignment with medical and development leadership Work collaboratively across the internal team to ensure that the lung cancer portfolio is progressing in line with both scientific excellence and commercial ambition Qualifications
Required: A minimum of 8 years of relevant experience in oncology commercial strategy, new product planning, launch readiness, or asset strategy roles Required: Strong track record in solid tumors, ideally with direct or adjacent lung cancer experience Required: Significant experience in early-stage commercialization, including product concept shaping, indication assessment, and early launch strategy Required: Ability to partner effectively with R&D, including familiarity with oncology clinical trial design, regulatory pathways, and biomarker-driven development Required: Demonstrated understanding of the US oncology landscape and stakeholder needs; experience & understanding with EU and other major markets Required: Strong scientific acumen combined with a highly strategic mindset and the ability to navigate ambiguity in a pre-commercial environment Required: Experience working in global or cross-regional roles, ideally within biotech or fast-paced oncology-focused companies Preferred: Advanced degree (PhD, PharmD, MD, or MBA) strongly preferred
#J-18808-Ljbffr
Director, Lung Cancer Portfolio, reporting to the VP of Lung Cancer Therapies, based in New Jersey, US. This strategic, science-driven leader shapes the future of a high-priority oncology indication, focusing on new product planning and early commercial strategy. The role requires hands-on leadership, deep oncology market insight, and the ability to position early assets for future success in a global environment, with presence in the US and Germany. Responsibilities
Lead global commercial strategy development for the lung cancer portfolio, with a focus on indication prioritization, early positioning, and value-focused lifecycle strategy Drive new product planning activities from preclinical/early clinical through registrational development, supporting strategic TPP shaping, unmet need assessment, competitive differentiation, and commercial viability Partner cross-functionally with R&D, clinical development, translational research, regulatory, and medical affairs to embed commercial perspectives into key decisions Lead or co-lead commercial input into early launch readiness planning, with emphasis on evidence strategy, access considerations, and strategic stakeholder engagement Contribute to cross-functional governance processes, development strategy forums, and scenario planning efforts Support external interactions where needed (e.g., advisory boards, co-development partners, select KOL discussions) in alignment with medical and development leadership Work collaboratively across the internal team to ensure that the lung cancer portfolio is progressing in line with both scientific excellence and commercial ambition Qualifications
Required: A minimum of 8 years of relevant experience in oncology commercial strategy, new product planning, launch readiness, or asset strategy roles Required: Strong track record in solid tumors, ideally with direct or adjacent lung cancer experience Required: Significant experience in early-stage commercialization, including product concept shaping, indication assessment, and early launch strategy Required: Ability to partner effectively with R&D, including familiarity with oncology clinical trial design, regulatory pathways, and biomarker-driven development Required: Demonstrated understanding of the US oncology landscape and stakeholder needs; experience & understanding with EU and other major markets Required: Strong scientific acumen combined with a highly strategic mindset and the ability to navigate ambiguity in a pre-commercial environment Required: Experience working in global or cross-regional roles, ideally within biotech or fast-paced oncology-focused companies Preferred: Advanced degree (PhD, PharmD, MD, or MBA) strongly preferred
#J-18808-Ljbffr